NCT03418818Active, not recruiting
FAZA PET/MRI Sarcoma
A Prospective Study of Hypoxia Imaging in Patients With Soft Tissue Sarcoma Using Positron Emission Tomography (PET) With 18F-Fluoroazomycin Arabinoside (18F-FAZA) in Combination With MRI
Source: ClinicalTrials.gov · Last updated 10 Aug 2026
Brief summary (registry, in English)
This is a dual arm, single centre, investigator initiated study to investigate the use of FAZA-PET in combination with MRI. FAZA is an investigational radiotracer used in PET scans. FAZA PET/MRI will be used to measure hypoxia in sarcoma tissues and will occur for: Arm A: before neo-adjuvant radiation/chemotherapy treatment; Arm B: before surgery (optional). After the FAZA PET/MRI scan, patients will be followed up via telephone, 48 hours after the scan, to see if there are any side effects due to FAZA. Up to 50 patients enrolled in Arm B will receive pimonidazole approximately 16-20 hours before surgery.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 70 (estimated)
- First submitted
- 26 Jan 2018
- Start date
- 27 Mar 2018
- Primary completion date
- 31 Oct 2028
- Lead sponsor
- University Health Network, Toronto
- Diseases
- Sarcoma
- NCT number
- NCT03418818
What you commit to
- Study type: Interventional
- Planned participants: 70
- From 27 Mar 2018 to the primary completion date, 31 Oct 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous radiotherapy to intended treatment volumes.
- Previous systemic therapy
Other illness
- Active malignancy other than sarcoma
- Failure to provide written informed consent
Age
- Age less than 18 years old
Other
- Unable to remain supine for at least 60 minutes
- Pregnancy or breast feeding
- Contraindication for MR as per current institutional guidelines.
Who the study is looking for
- Age ≥ 18 years
- Patients with either: high-risk extremity STS (g2-3, \> 10 cm largest dimension, and leiomyosarcoma, synovial sarcoma, malignant peripheral nerve sheath tumour, or undifferentiated pleomorphic sarcoma), or: high-risk RPS (g2-3, and leiomyosarcoma or dedifferentiated liposarcoma)
- Intention to treat using radiotherapy/chemotherapy/surgery according to the current treatment policies of the Sarcoma Site Group of PM
- A negative serum pregnancy test within the two-week interval immediately prior to PET-MR imaging, for women of child-bearing age
- Ability to provide written informed consent to participate in the study
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University Health Network Coordinator of this site? Confirm its status | Toronto | Canada | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.